ADMA CEO exercises options, sells 21K shares
ADMA Biologics President and CEO Adam S. Grossman reported a mix of option exercise and share sales.
Rhea-AI Filing Summary
ADMA Biologics President and CEO Adam S. Grossman reported a mix of option exercise and share sales. On February 17, 2026, he exercised a stock option for 15,000 shares at $5.40 per share, converting it into 15,000 shares of common stock. He then sold a total of 21,000 common shares in open-market transactions at $16.08 per share under a Rule 10b5-1 trading plan.
After these transactions, he directly holds 2,284,379 common shares. He also has indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC. Footnotes note multiple unvested RSU awards granted between 2022 and 2026 that vest over four years and settle in common stock, plus previously acquired shares reflecting prior RSU vesting and purchases.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Grossman Adam S
Role
President and CEO
Sold
21,000 shs ($338K)
Approx. gross sale proceeds
$338K
Approx. exercise cost
$81K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $5.40 | $81K |
| Sale | Common Stock | 15,000 | $16.08 | $241K |
| Sale | Common Stock | 6,000 | $16.08 | $96K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 705,950 contracts (Direct);
Common Stock — 2,284,379 shares (Direct);
Common Stock — 1,724,383 shares (Indirect, See Footnote)
Footnotes (8)
- F1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
- F2. The price reported in Column 4 is the price at which the shares were sold.
- F3. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
- F4. (continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
- F5. (continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
- F6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
- F7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
- F8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ADMA (ADMA) CEO Adam Grossman report in this Form 4?
Adam Grossman reported an option exercise and share sales. He converted 15,000 option shares into common stock, then sold 21,000 common shares in open-market trades executed under a pre-arranged Rule 10b5-1 trading plan.
What stock option activity did the ADMA CEO report?
He exercised a stock option for 15,000 shares of ADMA common stock. The option had an exercise price of $5.40 per share and was reported as an exercise or conversion of a derivative security on February 17, 2026.
What is the Rule 10b5-1 trading plan mentioned in the ADMA filing?
The filing states the sales were made under a Rule 10b5-1 plan. This plan, entered with Fidelity on November 14, 2025, pre-scheduled trades in advance, allowing the CEO’s share sales to follow a predetermined program.
What unvested RSUs does the ADMA CEO hold according to the Form 4?
Footnotes describe several unvested RSU grants from 2022 to 2026. These include awards such as 282,529 RSUs granted February 9, 2026 and other large tranches, all vesting over four years and settling in ADMA common stock upon vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
